Tag: interim

Suominen Corporation’s stock exchange release on June 8, 2026, at 10:30 a.m. (EEST)

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Elauwit Connection, Inc. (NASDAQ: ELWT) resulting from allegations that Elauwit may have issued materially misleading business information to the investing public.

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health”, or the “Company”) announces that, further to its press release dated June 2, 2026, the Autorité des marchés financiers, as the Company’s principal regulator, has granted a management cease trade order (the “MCTO”) under National Policy 12-203 – Management Cease Trade Orders.